248 related articles for article (PubMed ID: 12072661)
1. Pharmacology of acid suppression in the hospital setting: focus on proton pump inhibition.
Pisegna JR
Crit Care Med; 2002 Jun; 30(6 Suppl):S356-61. PubMed ID: 12072661
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
3. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
Cheer SM; Prakash A; Faulds D; Lamb HM
Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
[TBL] [Abstract][Full Text] [Related]
4. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Hatlebakk JG; Berstad A
Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
[TBL] [Abstract][Full Text] [Related]
6. Switching between intravenous and oral pantoprazole.
Pisegna JR
J Clin Gastroenterol; 2001 Jan; 32(1):27-32. PubMed ID: 11154164
[TBL] [Abstract][Full Text] [Related]
7. Pantoprazole.
Poole P
Am J Health Syst Pharm; 2001 Jun; 58(11):999-1008. PubMed ID: 11402494
[TBL] [Abstract][Full Text] [Related]
8. Pantoprazole: a new proton pump inhibitor.
Jungnickel PW
Clin Ther; 2000 Nov; 22(11):1268-93. PubMed ID: 11117653
[TBL] [Abstract][Full Text] [Related]
9. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
Ramdani A; Mignon M; Samoyeau R
Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410
[TBL] [Abstract][Full Text] [Related]
10. Stress-related mucosal disease in the critically ill patient: risk factors and strategies to prevent stress-related bleeding in the intensive care unit.
Steinberg KP
Crit Care Med; 2002 Jun; 30(6 Suppl):S362-4. PubMed ID: 12072662
[TBL] [Abstract][Full Text] [Related]
11. Clinical experience with pantoprazole in gastroesophageal reflux disease.
Avner DL
Clin Ther; 2000 Oct; 22(10):1169-85; discussion 1149-50. PubMed ID: 11110229
[TBL] [Abstract][Full Text] [Related]
12. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion.
Metz DC
Digestion; 2000; 62(2-3):73-81. PubMed ID: 11025353
[TBL] [Abstract][Full Text] [Related]
13. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Thomson AB
Curr Gastroenterol Rep; 2000 Dec; 2(6):482-93. PubMed ID: 11079051
[TBL] [Abstract][Full Text] [Related]
14. The pharmacology and clinical relevance of proton pump inhibitors.
Katz PO; Frissora C
Curr Gastroenterol Rep; 2002 Dec; 4(6):459-62. PubMed ID: 12441035
[TBL] [Abstract][Full Text] [Related]
15. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.
Nishioka K; Nagao T; Urushidani T
Biochem Pharmacol; 1999 Oct; 58(8):1349-59. PubMed ID: 10487539
[TBL] [Abstract][Full Text] [Related]
16. Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression.
Trépanier EF
Can J Gastroenterol; 2000 Nov; 14 Suppl D():11D-20D. PubMed ID: 11110607
[TBL] [Abstract][Full Text] [Related]
17. Continuing development of acid pump inhibitors: site of action of pantoprazole.
Shin JM; Besancon M; Prinz C; Simon A; Sachs G
Aliment Pharmacol Ther; 1994; 8 Suppl 1():11-23. PubMed ID: 7514042
[TBL] [Abstract][Full Text] [Related]
18. The basis of differentiation of PPIs.
Sachs G; Shin JM
Drugs Today (Barc); 2004 Mar; 40 Suppl A():9-14. PubMed ID: 15190382
[TBL] [Abstract][Full Text] [Related]
19. Proton pump activation in stimulated parietal cells is regulated by gastric acid secretory capacity: a human study.
Metz DC; Ferron GM; Paul J; Turner MB; Soffer E; Pisegna JR; Bochenek WJ
J Clin Pharmacol; 2002 May; 42(5):512-9. PubMed ID: 12017345
[TBL] [Abstract][Full Text] [Related]
20. Effect of pantoprazole on 24-h intragastric pH and serum gastrin in humans.
Londong W
Aliment Pharmacol Ther; 1994; 8 Suppl 1():39-46. PubMed ID: 8180293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
